DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Seribantumab is an investigational drug.
There have been 6 clinical trials for Seribantumab. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2020.
The most common disease conditions in clinical trials are Breast Neoplasms, Fallopian Tube Neoplasms, and Neoplasms. The leading clinical trial sponsors are Merrimack Pharmaceuticals, Sanofi, and Elevation Oncology.
There are three US patents protecting this investigational drug and ten international patents.
Recent Clinical Trials for Seribantumab
|A Phase 2 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Cancer||Elevation Oncology||Phase 2|
|Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer||Merrimack Pharmaceuticals||Phase 2|
|Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors||Sanofi||Phase 1|
Top disease conditions for Seribantumab
Top clinical trial sponsors for Seribantumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Seribantumab||Start Trial||Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors||Merrimack Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|Seribantumab||Start Trial||Salt of EGFR inhibitor, crystalline form and uses thereof||SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)||Start Trial|
|Seribantumab||Start Trial||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|